Literature DB >> 870237

The effects of hyaluronidase on coronary blood flow following coronary artery occlusion in the dog.

J Askenazi, L D Hillis, P E Diaz, M A Davis, E Braunwald, P R Maroko.   

Abstract

In an attempt to determine the mechanism by which hyaluronidase reduces myocardial injury following coronary artery occlusion, myocardial blood flow was studied in 20 open-chest dogs with occlusion of the left anterior descending coronary artery. Ten dogs served as controls, and 10 received hyaluronidase (500 NF units/kg) intravenously 20 minutes after occlusion. At 15 minutes and at 6 hours after occlusion, regional myocardial blood flow in the epicardial and endocardial halves of both ischemic and nonischemic zones were determined with radiolabeled microspheres. Mean arterial pressure, heart rate, and cardiac output were similar in the untreated and treated dogs through the 6 hours of the experiment. Moreover, regional blood flow to nonischemic myocardium (areas without epicardial S-T segment elevation 15 minutes after occlusion) was similar in the two groups 15 minutes and 6 hours after occlusion. Fifteen minutes after occlusion, the flow to the ischemic myocardium subjacent to sites with S-T segment elevation exceeding 2 mV) in the untreated group was: transmural, 28.1 +/- 2.2 (mean +/- SE) ml/min per 100 g; endocardial, 20.7 +/- 1.8; and epicardial, 38.5 +/- 3.1. The endocardial-epicardial flow ratio was 0.56 +/- 0.04. Six hours after occlusion, the untreated group demonstrated a further decrease in blood flow to the ischemic myocardium: transmural, 15.2 +/- 1.4 ml/min per 100 g; endocardial, 6.8 +/- 1.1; and epicardial, 24.3 +/- 1.9. The endocardial-epicardial flow ratio fell to 0.28 +/- 0.04. In contrast, the hyaluronidase-treated dogs showed no further reduction in blood flow to ischemic myocardium 6 hours after occlusion: transmural, 30.3 +/- 3.1 ml/min per 100 g; endocardial, 21.3 +/- 2.5; and epicardial, 38.8 +/- 3.8. These regional myocardial flows were significantly higher than those of the untreated dogs 6 hours after occlusion. Thus, salvage of damaged myocardium by hyaluronidase might be explained by its beneficial effect on collateral blood flow to the ischemic tissue, though this effect on collateral flow could be the consequence rather than the cause of this salvage.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870237     DOI: 10.1161/01.res.40.6.566

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  Influence of hyaluronidase on infarct size following experimental coronary occlusion of short (90') or long (24 hrs) duration.

Authors:  M Hofmann; M Hofmann; W Schaper
Journal:  Basic Res Cardiol       Date:  1980 Mar-Apr       Impact factor: 17.165

2.  Effect of hyaluronidase on mortality and morbidity in patients with early peaking of plasma creatine kinase MB and non-transmural ischaemia. Multicentre investigation for the limitation of infarct size (MILIS).

Authors:  R Roberts; E Braunwald; J E Muller; C Croft; H K Gold; T D Hartwell; A S Jaffe; S M Mullin; C Parker; E R Passamani
Journal:  Br Heart J       Date:  1988-10

3.  Assessment of the efficacy of interventions to limit ischemic injury by direct measurement of intramural carbon dioxide tension after coronary artery occlusion in the dog.

Authors:  L D Hillis; S F Khuri; E Braunwald; R A Kloner; D Tow; E Barsamian; P R Maroko
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

4.  Exerimental coronary artery occlusion. III. The determinants of collateral blood flow in acute coronary occlusion.

Authors:  W Schaper
Journal:  Basic Res Cardiol       Date:  1978 Nov-Dec       Impact factor: 17.165

5.  Long-term preservation of ischemic myocardium after experimental coronary artery occlusion.

Authors:  D Maclean; M C Fishbein; E Braunwald; P R Maroko
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

6.  Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog.

Authors:  R L Engler; G W Schmid-Schönbein; R S Pavelec
Journal:  Am J Pathol       Date:  1983-04       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.